Rheumnow

Dr Jack Cush reviews the news and journal articles from the past week. Many interesting early reports on the use of rheumatic drugs, including hydroxychlorquine, IL-6 inhibitors, canakinumab, baricitinib and colchicine. Below are some of the links or citations of interest.

Dr. Artie Kavnaugh from UCSD runs journal club and discusses Journal Article: Mathian A, et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomized clinical trial. Annals of Rheumatic Disease 2020; Mar;79(3):339-34 https://bit.ly/2S3VOBc

Dr. Jack Cush reviews the 2 minute Video Virtual Joint exam.

Dr Jack Cush reviews the news, journal reports, twitter feed and COVID developments from the past week on RheumNow.com

Dr. Alvin Wells gives a primer on Telerheumatology and Telemedicine in the era of COVID-19. 30 minute lecture is followed by stimulating 30 minutes of Q&A

Dr Jack Cush reviews the news, journal articles and new ACR COVID-19 guidelines from the past week on RheumNow.com

Dr. Jack Cush reviews the appproach to evaluating fever in adults suspected of having a rheumatic disease, Stills disease or autoinflammatory conditions. Presentation, disease criteria and genetic testing are discussed. For more information on this subject go to StillsNow.com

Dr. Jack Cush reviews the appproach to evaluating fever in adults suspected of having a rheumatic disease, Stills disease or autoinflammatory conditions. Presentation, disease criteria and genetic testing are discussed. For more information on this subject go to StillsNow.com

Dr. Jack Cush reviews the safety of biologic agents and newer therapies for rheumatoid arthritis and inflammatory arthritis

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Part III - Audience Questions 54:14 How comfortable are you with telephone or televideo visits with your patients? 57:24 A Covid (+) patient was treated at home, how long after the infection till you resume the biologic? 1:00:00 PsA Case, post TKR, off adalimumab, now flaring skin and joints and has low grade fever, cough and aches; is it safe to restart the TNF inhibitor in the COVID-19 era or what would you do? 1:03:58 Is hydroxychloroquine protective; Should we screen before IV infusions? 1:04:29 What dose of prednisone is immunosuppressive? 1:05:50 Is it Hydroxychloroquine may not be helpful in HIV and chikungunya? 1:07:03 What are your policies on seeing new patient consults in clinic? 1:09:10 What will happen to ongoing clinical trials in rheumatology? 1:11:41 Are you having a hard time getting HCQ for your patients? 1:12:04 Should we look at COVID-19 viral loads? 1:13:12 Who wears masks in your clinic – doctors; staff; patients? 1:16:22 During the PPE shortage, can masks be reused? 1:18:33 How good/

Part II – Audience Questions 33:32 What about the timing of hydroxychloroquine use and for how long? 34:50 Should patients on bDMARDs or tsDMARDs (because of presumed risk) not go to work and should we write letters for such people? 37:05 Bush Administration disaster preparedness guidelines and supporting patients 39:06 What infusions should we not do? Denosumab? Zolendronic acid? 41:09 What to do about tocilizumab infusions being COVID diverted? What are the alternatives? 44:09 Should you start your lupus or RA patient on hydroxychloroquine or a new biologic in this era? 46:58 A patient has a resolved COVID-19 infection, would you start a biologic if needed? 47:21 Is anyone worried about the cardiotoxicity of hydroxychloroquine or chloroquine? 48:42 Would you the doctor, self-medicate, or prophylax, with HCQ if you have new onset suspicious symptoms? 50:04 Should rheumatologists do inpatient consults during the COVID? 51:30 If tests were universally available, would you test all your rheumatology patients f

Part I Panel Questions 0:00 Introduction 1:22 How has the COVID-19 pandemic affected you? 4:09 What’s the most common question you’re getting and what is your response? 8:06 What adjustments have you made in your practice or how has your practice changed? 13:13 Things we are not doing anymore… 13:40 Questions amongst panelists 13:33 A Kavanaugh (to K Winthrop) What’s the evidence favoring the evidence hydroxychloroquine (French Study) 16:40 J Cush (to C Calabrese) Is azithromycin an effective COVID therapy? 17:45 C Calabrese (to K Winthrop) What about “Universal Masking”? 20:24 A Matsumoto (to ID docs CC, KW) When can patients (or healthcare workers) resume infliximab infusions after being symptomatic? 24:23 A Wells (to AK) what to do with trainees during this “shutdown”? 25:55 A Wells (to CC) What about the new 15 min test vs the ‘real time' (PCR) test? 26:22 J Cush on the Global Rheumatology Alliance - rheum-covid.org 27:25 Are Rheumatic patients “at-risk” for COVID-19 infection or worse o

Q&A with the Experts: Drs. Cassie Calabrese, Jack Cush, Artie Kavanaugh, Alan Matsumoto, Alvin Wells & Kevin Winthrop

Dr. Jack Cush reviews the news on COVID-19 and FDA actions this past week. Be sure to check out: - COVID-19 Town Hall for Rheumatologists - ID Specialist Dr. Jade Le answers questions about COVID issues https://t.co/o79FJ8QhDY - RheumNow interviews Dr @philipcrobinson about the COVID-Global Rheumatology Alliance Registry https://t.co/pOlm58QkZD

Dr. Jade Le is an infectious disease specialist in Dallas, TX She addresses PPE, masks, Package delivery, Managing suspicious Sxs, Testing and consulting ID

Interview with Dr. Philip Robinson, Univ. of Queensland

Why the Virtual Visit is the Future of Rheumatology

Dr Jack Cush reviews the news and COVID developments from this past week